Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
Date:2/28/2008

VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 9:00 a.m. ET on Tuesday, March 4, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Dick Anderson and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 566-5775 or (210) 234-0004. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 396-7637 or (203) 369-0522. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. MannKind to Present at the Wachovia 2008 Healthcare Conference
3. MannKind to Present at the Piper Jaffray Healthcare Conference
4. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. MannKind to Present at the UBS Global Life Sciences Conference
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
9. Pharmion Corporation Announces 2007 Operating Results
10. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
11. VLST Corporation Announces Board and Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
Breaking Biology News(10 mins):